New eczema pill shows promise in Mid-Stage trial
NCT ID NCT07441395
First seen Mar 10, 2026 · Last updated May 20, 2026 · Updated 11 times
Summary
This study tests a new daily pill, soquelitinib, in 200 adults with moderate to severe atopic dermatitis (eczema). Participants take the drug or a placebo for 12 weeks. Doctors track skin improvements and side effects to see if the drug is safe and works better than a dummy pill.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Corvus Clinical Trials
RECRUITINGSouth San Francisco, California, 94080, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.